
Sigachi Industries Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
Yes
Order
Yes
Capex
Yes
3 of 5 growth signals are positive.
Full analysisRevenue guidance
Category 2- Sigachi Industries expects top-line growth of approximately 30% for the current financial year, driven by added capacities and new products like PureCoat and UltraMod.
- The company has a sustainable revenue growth outlook of 25%-30% annually over the next few years.
- MCC segment grew 15%-20%, outpacing the global MCC growth of about 10%, with market share gains from better pricing, service, and a wide product range.
- API segment capacity is being expanded from 100 KL to 250 KL, with full utilization expected by mid-FY26. API revenue share is targeted to reach around 30% of total revenue this year.
- The CCS and O&M segments are also poised for growth with ongoing and planned capex, contingent on regulatory approvals.
- The Gulf operations and Middle East ventures are expected to contribute revenues starting next financial year.
- Overall, management is confident of maintaining or improving EBITDA margins alongside revenue growth.
See what Sigachi Industries management said on margin guidance — free account, 30 seconds.
Fundraise plans
YesSee what Sigachi Industries management said on order book — free account, 30 seconds.
Capex plans
Yes- Ongoing capex includes API expansion and CCS expansion with timelines around 12 to 18 months.
- New coating product capacities (PureCot and Ultramod) have commenced operations and are in sampling phase.
- Plan to increase MCC capacity soon due to 50% utilization of current expanded capacity and strong demand.
- Future MCC capacity expansions are likely within 2 to 3 years, driven by demand and consumption growth.
- Capex also planned for setting up a manufacturing plant in the USA to reduce freight and logistics costs.
- Company is seeking umbrella approval for raising funds via unsecured convertible bonds (FCCB) to support growth capex.
- CCS plant project delayed due to pending pollution control board approval; progress expected once approvals are received.
- Focus on incremental capex only after thorough cost-benefit analysis to ensure it supports business growth.
Track Sigachi Industries — get its next earnings analysis in your feed
How does Sigachi Industries rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Sigachi Industries rank in Pharmaceuticals & Biotechnology?
Compare Sigachi Industries against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Sigachi Industries's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem